Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OvaGene Oncology has completed a major licensing and collaboration agreement with The Moffitt Cancer Center.
Subscribe to our email newsletter
The agreement provides OvaGene with worldwide rights to develop and commercialize proprietary microRNA-based assays that predict drug response for currently used cancer treating drugs.
The proprietary assays were developed and validated at the Moffitt Cancer Center under the leadership of Johnathan Lancaster.
The technology, licensed from The Moffitt Cancer Center, includes proprietary microRNA-based biomarkers that can be used to predict response to chemotherapy in a variety of tumor types.
OvaGene chief scientific officer William Ricketts said that they are looking forward to developing and commercializing the cancer microRNA diagnostic assay related to drug response.